

Dr. Dibakar Podder
Curriculum Vitae

Correspondence:

Department of Clinical Hematology and Cellular Therapies,
Tata Medical Center,
14, Main Arterial Road (E-W), DH Block, New town, Kolkata: 700160.
dibakar.hematology@gmail.com

Current Position:

Associate Consultant
Department of Clinical Hematology and Cellular Therapies
Tata Medical Center

Areas of Interest:

Plasma cell Neoplasm, Multiple Myeloma, MGUS, MGRS, Amyloidosis
Lymphomas
Hemoglobinopathies, Aplastic Anemia, Coagulopathies
Stem Cell transplant and Cellular therapies

Education

MBBS, Agartala Government Medical College, Agartala

August 2005 — January 2010

MD (Pathology), Kasturba Medical College, Manipal, Udupi

May 2012 — May 2015

Post Doctoral Fellowship (Clinical Hematology and Stem Cell transplant), Tata Medical Center, Kolkata

February 2016 — June 2018

DM (Clinical Hematology), Medical College and Hospital, Kolkata

August 2018 — August 2021

Clinical Experience

Assistant Professor (Tripura Medical College), Tripura

September 2016 — February 2016

Junior Consultant (CNCI), Kolkata

October 2021 — February 2022

Clinical Associate (Tata Medical Center), Kolkata

March 2022 — December 2022

Junior Consultant, (Tata Medical Center), Kolkata

January 2023 — January 2024

Associate Consultant, (Tata Medical Center), Kolkata

January 2024- present

Department of Clinical Hematology and Cellular Therapies

Conference Papers:

National:

1. Pineal gland tumors- a report of two cases. NEUROPATH CME; 2014
2. Clinicopathologic and radiologic features of thymoma in 10 cases based on 2004 WHO classification- Annual Pathology conference, Goa; 2015
3. Cytopathology of mucoepidermoid carcinoma of salivary glands
4. Clinicopathological Characteristics and Outcome in Patients of Primary CNS Lymphoma Treated with Modified De-Angelis Protocol: An Audit; SOHO 2018, Houston
5. Case series of hairy cell leukemia- a rare low-grade B cell lymphoma with unusual presentation. BESHCON 2018, Kolkata
6. MPN with T lymphoblastic lymphoma associated with a novel cytogenetic abnormality- a case report: HEMATOCON 2019, Delhi
7. Safety and Efficacy of low dose thalidomide in transfusion dependent E-beta Thalassemia. BESHCON 2021, Kolkata

International

1. BK virus reactivations in patients undergoing Allogeneic stem cell transplant-an audit. APBMT 2022, Cochin
2. Efficacy and safety of Ponatinib in chronic phase CML- Real world data from a tertiary care center- HEMATOCON 2022, Kolkata
3. Clinical Characteristics and Outcome of Extranodal NK T-Cell Lymphoma Nasal Type: A Decade's Experience- SOHO 2024, Houston
4. Early Impressions With Use of BCMA-Directed Therapy: Elranatamab in Multiply Relapsed/Refractory Multiple Myeloma: A Safety and Efficacy Analysis in a Tertiary Cancer Center in India- SOHO 2024, Houston
5. A journey through understanding and managing Waldenstrom's Macroglobulinemia (WM): 13 years of Insight- EHA 2025, Milan
6. A retrospective analysis of AL-AMYLOIDOSIS in a tertiary care center in India- EHA 2025, Milan
7. Solitary plasmacytoma – a real world outcome analysis from India- EHA 2025, Milan
8. Kumar, J., Pincha, R., Radhakrishnan, V. S., Tamboli, N., Nag, A., **Podder, D.**, Chattopadhyay, D., Bhawe, S. J., Das, S., Parihar, M., Rath, A., Vinarkar, S., Mukhopadhyay, S., Chakraborty, S., Mishra, D. K., Chandy, M., & Nair, R. (2023). Safety and Efficacy of Bortezomib-Pomalidomide-Dexamethasone (VPD) As Novel Induction Therapy in Newly-Diagnosed Multiple Myeloma: Updated Data from an Ongoing Single Arm Phase-II Investigator- Initiated Clinical Trial (PRIME Study). *Blood*, 142(Supplement 1), 6713. <https://doi.org/10.1182/blood-2023-186903>
9. **Podder Dibakar**; Bhattacharyya Subhadip Pincha Rajat Sahoo Aradhana KT Baalamurugan Shinde Suchita Mundra Pallav Chattopadhyay Debranjani Ghosh Shouriyio Nag Arijit Kumar Jeevan Zameer Lateef Arun Indu Achari Rimpa Nair Reena. Clinical Characteristics and Outcome of Extranodal NK T-Cell Lymphoma Nasal Type: A Decade's Experience. *Clinical Lymphoma Myeloma and Leukemia* 24. S230. 10.1016/S2152-2650(24)00910-8.
10. **Podder Dibakar** Patil Noopur Brahma Anupam Shewale Sundar Javed Rizwan Chattopadhyay Debranjani Ghosh Shouriyio Nag Arijit Kumar Jeevan Rath Ashish Vinarkar Sushant Parihar Mayur Mishra Deepak Chakraborty Subhosmito Nair Reena. (2024). *Early Impressions With*

Use of BCMA-Directed Therapy: Elranatamab in Multiply Relapsed/Refractory Multiple Myeloma: A Safety and Efficacy Analysis in a Tertiary Cancer Center in India. *Clinical Lymphoma Myeloma and Leukemia*. 24. S559. 10.1016/S2152-2650(24)01685-9.

11. Ghosh, Shouriyi Sinha Subir Chatterjee Sutapa Nag Arijit Chattopadhyay Debranjani **Podder Dibakar** Kumar Jeevan Javed Rizwan Rath Asish Mishra Deepak Vinarkar Sushant Parihar Mayur Nair Reena. Outcomes of Azacytidine-Venetoclax Th in Upfront and Relapsed/Refractory Setting in Acute Myeloid Leukemia: Real World Experience from India. *Clinical Lymphoma Myeloma and Leukemia*. 24. S171. 10.1016/S2152-2650(24)00509-3
12. Pincha Rajat Ghosh Shouriyi **Podder Dibakar** Kumar Jeevan Nag Arijit Javed Rizwan Chattopadhyay Debranjani Mishra Deepak Parihar, Mayur Nair Reena. Outcome of Autologous Stem Cell Transplantation in High-Risk Multiple Myeloma: A Single-Center Experience. *Clinical Lymphoma Myeloma and Leukemia*. 24. S241. 10.1016/S2152-2650(24)00981-9.

Publications

1. Shah, B., **Podder, D.**, Ghosh, S. *et al.* Real World Outcome of Primary Plasma Cell leukemia - a Retrospective Analysis from a Tertiary Care Center from Eastern India. *Indian J Hematol Blood Transfus* (2026). <https://doi.org/10.1007/s12288-026-02350-6>
2. Gupta, P., Ghosh, S., **Podder D**; Roy, S. *et al.* In Search for the Ideal All-Trans-Retinoic Acid Dose in Acute Promyelocytic Leukemia: Striking the Balance Between Drug Toxicity and Measurable Residual Disease Clearance. *Indian J Hematol Blood Transfus* (2025). <https://doi.org/10.1007/s12288-025-02230-5>
3. Nag A, Kt B, Kumar J, Ghosh S, **Podder D**, Chattopadhyay D, Saha S, Javed R, Chatterji S, Rath A, Nair R, Bharat S. Bioequivalent Letermovir Usage for Prophylaxis in Haploidentical Stem Cell Transplantation at High Risk of CMV Reactivation: A Report of Two Cases From India. *Cureus*. 2025 Apr 26;17(4):e83035. doi: 10.7759/cureus.83035. PMID: 40432636; PMCID: PMC12106792.
4. T, B.K., Ghosh, S., **Podder, D.** *et al.* Ponatinib in Chronic Myeloid Leukaemia Refractory To Multiple Tyrosine Kinase Inhibitors: Data from a Tertiary Care Centre in India. *Indian J Hematol Blood Transfus* (2025). <https://doi.org/10.1007/s12288-025-02184-8>
5. VS, R., **Podder D.**, H, M. *et al.* Primary Central Nervous System Lymphoma: Long-Term Treatment Clinicopathological Characteristics and Outcome in Patients of Primary CNS Lymphoma Treated with Modified De-Angelis Protocol: An Audit SOHO 2018 DOI: 10.1016/j.cml.2018.07.210 Outcomes and Cost-Analysis from a Retrospective Study of High-Dose Methotrexate Based Chemoimmunotherapy and Reduced Dose Radiation Therapy Approach. *Indian J Hematol Blood Transfus*(2021). <https://doi.org/10.1007/s12288-021-01444-7>
6. Shinde S, Guntiboina VA, Nag A, **Podder D**, Chattopadhyay D, Kumar J, Bhawe S, Mishra DK, Chandy M, Nair R. Melphalan-associated encephalopathy following autologous stem cell transplant: a transplanters' nightmare! *Blood Cell Ther*. 2024 Mar 15;7(2):33-36. doi: 10.31547/bct-2023-025
7. Nayak Deepak M, Manohar Chethan, **Podder Dibakar**, Kakkar Richa. EDTA- Induced lymphoid clumping in follicular lymphoma- a case report. *Int j clin surg adv* 2013; 1(2):12-15
8. **Podder D**, Monappa V, Shetty P. Soft tissue chondroma: a rare tumor presenting as cutaneous nodule. *Our Dermatol Online*. 2014;6(2):1-3

Clinical trials


Indication	Sponsor Indian/ Global	Trial Phase	No. of Subjects Screened/Randomized/Completed			Year	Recruitment Period
Relapsed Lymphoid Malignancies	Global	I	0	0	0	2025-Ongoing	2025-Ongoing
Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia	Global	III	1	1	0	2023-Ongoing	2023-ongoing
Relapsed and Refractory Multiple myeloma	Global	IV	7	7	3	2024-Ongoing	2024-Ongoing
High-risk Large B-cell Lymphoma	Global	III	2	2	0	2025-Ongoing	2025
Relapsed and Refractory Multiple myeloma	Global	III	19	18	0	2024-Ongoing	2024-2025
Newly Diagnosed Multiple Myeloma	Global	III	2	2	0	2025-Ongoing	2025-Ongoing
Relapsed Advanced Malignancies	Global	I	1	1	0	2025-Ongoing	2025-Ongoing
RRMM	Global	I/II	1	1	0	2025-Ongoing	2025

Membership

1. Indian Society of Hematology & Blood transfusion (ISHBT)
2. Bengal society of Hematology (BSH)
3. American Society of Hematology (ASH)
4. Society Of Hematologic Oncology (SOHO)
5. European Society Of Medical Oncology (ESMO)
6. Indian Myeloam Academic Groupe (IMAGe)
7. International Myeloma Society
8. International Society of Amyloidosis
9. European Hematology Association

ORCID ID:

<https://orcid.org/0000-0003-4486-5340>


14/4/2026



Hereby Certifies that
DIBAKAR PODDER
has completed the e-learning course
**ICH GOOD CLINICAL
PRACTICE E6(R3)**

with a score of

100%

on

26/03/2026

this e-learning course has been formally recognised for its quality and content by
the following organisations and institutions:



*This ICH E6 GCP Investigator Site Training meets the Minimum Criteria for ICH
GCP Investigator Site Personnel Training identified by **TransCelerate BioPharma**
as necessary to enable mutual recognition of GCP training among trial sponsors.*

Global Health Training Centre
globalhealthtrainingcentre.org/elearning

Certificate Number 608b6435-f7be-4124-a177-9778e104b749 Version number 0

Podder
30-MAR-2026

Serial No : 1431

The Tripura State Medical Council

Bidurkarta Chowmuhani, Agartala - 799001




Certificate of Registration

I hereby certify that the following qualification/ additional qualifications as shown in column 5 has/have been entered in The Tripura State Medical Council Register.

Registration No : 001431

Date : 06.11.2021

Name	DR. DIBAKAR PODDER
Father's Name	Dillip Podder
Qualification as entered in the Tripura State Medical Council	M.B.B.S., A.G.M.C, Tripura University, 2011. M.D (Pathology), Manipal University, 2015.
Regd. No. Date and State Medical Council with which Registered.	Regn. No. 001431 dated 25.05. 2015 of The Tripura State Medical Council.
Additional Qualification entered in the Tripura State Medical Register.	D.M (Clinical Hematology) from West Bengal University of Health Sciences, 2021.
Address :	189, A.K. Road No. 7, Agartala, P.O : Ramnagar, Dist. : West Tripura, PIN - 799002.



IMPORTANT NOTICE

1. Report change of address and additional qualifications promptly.
2. All enquiries made by the Registrar should be answered without fail.
3. All persons registered under the Tripura Medical Council ACT 2010 are legally qualified to practice in Tripura.
4. Shall abide by code of Medical Ethics framed from time to time.

(Dr. Pinak Prasad Debbarma)
Registrar cum Secretary

The Tripura State Medical Council
Bidurkarta Chowmuhani, Agartala - 799001

Registrar cum Secretary
The Tripura State Medical Council

Agartala-799001

Podder
30-MAR-2026